Insulet Corporation (PODD) Initiates Voluntary Correction For Certain Omnipod Devices

Insulet Corporation (NASDAQ: PODD ) is among the 10 Most Oversold S&P 500 Stocks So Far in 2026 . The company is carrying out a voluntary correction for specific lots of Omnipod 5, Omnipod DASH, and Omnipod Insulin Management System, it said on May 26.

The medical device maker said it had identified a manufacturing issue during monitoring that could result in patients receiving less insulin than required, which could lead to high glucose levels and serious medical conditions like diabetic ketoacidosis (DKA).

According to Insulet Corporation’s (NASDAQ:PODD) press release, the manufacturing issue may cause insulin leakage outside the pod due to a small tear in the cannula above the skin, instead of being fully delivered into the body. This case is separate from a correction issued in March affecting certain Omnipod 5 Pods.

In other news, a Washington-based appeals court on Thursday reversed a $59 million verdict it had given in favor of Insulet against EOFlow for allegedly stealing trade secrets, after finding that the company had taken too long to bring the lawsuit against its Korean rival.

Insulet Corporation (NASDAQ:PODD) is a medical device company focused on developing, manufacturing, and selling insulin delivery systems for patients with diabetes.

While we acknowledge the potential of PODD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock .

READ NEXT: 10 Best Performing Defense Stocks So Far in 2026 and 10 Stocks That Will Make You Rich Over the Next Decade .